TRC160334|cas:1293289-69-6|西域试剂

TRC160334,95.0%

产品编号：Bellancom-141625| CAS NO：1293289-69-6| 分子式：C₁₄H₁₅N₃O₅S| 分子量：337.35

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-141625	￥2900.00	杭州北京（现货）
Bellancom-141625	￥4500.00	杭州北京（现货）
Bellancom-141625	￥9200.00	杭州北京（现货）
Bellancom-141625	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TRC160334

产品介绍

TRC160334 是缺氧诱导因子 (HIF) 羟化酶抑制剂。TRC160334 可用于研究缺血/再灌注损伤。

生物活性

TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury.

体外研究

TRC160334 (100~400 μΜ; 4 hours; Hep3B cells) results in dose-dependent stabilization of nuclear HIF-1.
TRC160334 (75~300 μM; 4 hours; Hep3B cells) results in dose-dependent transcriptional activation of HIF-1. TRC160334 shows a dose-dependent expression of HIF target genes such as EPO and adrenomedullin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Hep3B cells
Concentration:	100~400 μΜ
Incubation Time:	4 hours
Result:	Resulted in dose-dependent stabilization of nuclear HIF-1.

体内研究
(In Vivo)

TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen.
TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis.
TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley male rats (250–300 g)
Dosage:	0.1 and 0.3 mg/kg
Administration:	I.p.
Result:	Significantly reduced serum creatinine and blood urea nitrogen.

Animal Model:	Sprague-Dawley male rats (250–300 g)
Dosage:	0.3 and 0.6 mg/kg
Administration:	I.p.
Result:	Showed reducing trends for acute tubular necrosis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley male rats (250–300 g)
Dosage:	0.1 and 0.3 mg/kg
Administration:	I.p.
Result:	Significantly reduced serum creatinine and blood urea nitrogen.

Animal Model:	Sprague-Dawley male rats (250–300 g)
Dosage:	0.3 and 0.6 mg/kg
Administration:	I.p.
Result:	Showed reducing trends for acute tubular necrosis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley male rats (250–300 g)
Dosage:	0.1 and 0.3 mg/kg
Administration:	I.p.
Result:	Significantly reduced serum creatinine and blood urea nitrogen.

Animal Model:	Sprague-Dawley male rats (250–300 g)
Dosage:	0.3 and 0.6 mg/kg
Administration:	I.p.
Result:	Showed reducing trends for acute tubular necrosis.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (74.11 mM; ultrasonic and warming and heat to 80°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9643 mL	14.8214 mL	29.6428 mL
5 mM	0.5929 mL	2.9643 mL	5.9286 mL
10 mM	0.2964 mL	1.4821 mL	2.9643 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.17 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.17 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (6.17 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.17 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (6.17 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.17 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。